

Lisa A. Prosser, Ph.D.

Research Associate Professor
Child Health Evaluation and Research Unit
Division of General Pediatrics, University of Michigan Health System
300 N. Ingalls St., Room 6E14, Ann Arbor, MI 48109-5456
Phone: 734-232-1077, Fax: 734-764-2599
Email: lisapros@med.umich.edu

Education and Training:

8/84-5/88	B.A. Mathematics	Cornell University
9/90-6/92	M.S. Management	MIT Sloan School of Management
9/90-6/92	M.S. Technology & Policy	MIT
9/95-6/00	Ph.D. Health Policy	Harvard University

Academic, Administrative and Clinical Appointments:

8/88-8/90	Systems Consultant	Andersen Consulting
6/91-8/91	Health Policy Analyst	Abt Associates
8/92-7/95	Health Care Consultant	The Wilkerson Group
11/96-6/00	Research Assistant	Program for the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis
7/99-6/00	Research Fellow	Harvard Medical School
7/00-3/01	Instructor	Harvard Medical School
4/01-5/09	Assistant Professor	Harvard Medical School
5/09-present	Lecturer	Harvard Medical School
2/06-4/09	Assistant Professor (secondary)	Harvard School of Public Health
4/09-present	Adjunct Associate Professor	Harvard School of Public Health
1/08-9/08	Research Scientist	Henry Ford Health System
10/08-present	Research Associate Professor	University of Michigan Medical School

Research Interests

My major research interests are (1) economic evaluations of health interventions and (2) valuation of health for economic evaluations. My research focuses on policy-relevant topics concerning the cost-effectiveness of childhood interventions, such as a study of newborn screening for metabolic disorders that assesses how the inclusion of stress and anxiety associated with false positive tests affects the cost-effectiveness of expanded newborn screening programs. My research on the economic impact of influenza vaccination has been used in setting national vaccine policy for children and for prioritizing subgroups in vaccine shortage years. A study underway that assesses public values for avoiding influenza illness will provide data on the relative importance preventing influenza in different age and risk groups.

Another goal in my research is to advance the methods of valuing health for cost-effectiveness analysis, particularly for children's health states. A current project is testing new approaches for valuing temporary health states using a discrete choice experiment.

Grants

1997-1999	National MS Society (dissertation fellowship)	Doctoral Student	Cost-effectiveness of interferon beta-1a, interferon beta-1b and glatiramer acetate in patients with relapsing-remitting multiple sclerosis
2000-2002	CDC (through ACHP)	Co-Investigator	Cost-effectiveness of pneumococcal conjugate vaccine
2001-2002	CDC (through VSD)	Co-Investigator	Economic analysis of strategies to reduce influenza morbidity in children
2001-2004	CDC (through ATPM)	Co-Investigator	Costs and cost-effectiveness of administering influenza vaccination in non-traditional settings (Joint Initiative in Vaccine Economics)
2001-2004	AHRQ	Co-Investigator	RCT to reduce prescribing errors in hypertension
2002-2003	PhRMA Foundation	Principal Investigator	Are managed care decisions consistent with public preferences?
2003-2006	ELSI/NIH	Co-Investigator	Expanded newborn screening for metabolic disorders
2003-2006	NICHHD	Co-Investigator	Decision analysis of otitis media vaccination strategies
2004-2007	CDC	Co-Investigator	Joint Initiative in Vaccine Economics II
2004-2007	CDC	Consultant	Health values and treatment of pediatric type 2 diabetes
2005-2006	DACP Faculty Grant	Principal Investigator	Valuing children's health: A review of cost-effectiveness analyses for pediatric health interventions
2005-2006	CDC	Principal Investigator	Child maltreatment quality of life measurement tool
2005-2006	NLM/NIH	Co-Investigator	Methods for evaluating bioterrorism
2005-2010	NICHHD	Co-Investigator	Improving primary care to prevent childhood obesity

2006-2007	BSFC	Co-Investigator	Combining clinical effectiveness and cost effectiveness
2006-2007	HPHC Foundation	Principal Investigator	Economic barriers to obesity prevention and management in children
2007-2008	CDC	Principal Investigator	Cost-effectiveness of live attenuated influenza vaccine for children
2007-2010	CDC	Co-Investigator	Joint Initiative in Vaccine Economics III

Current Research Activities

Title: Expanded newborn screening for metabolic disorders

Description: Cost-effectiveness analysis of expanded newborn screening program for metabolic disorders. Study will include costs of false positives and will measure health-related quality-of-life for treatments and outcomes.

Role: Co- investigator

Title: Joint Initiative in Vaccine Economics II

Description: A series of economic studies that will inform policy decisions about new vaccines and vaccine delivery programs, including an online discrete choice experiment to value influenza-related health outcomes (lead investigator) and a utility assessment project for varicella zoster outcomes in the elderly (co-investigator).

Role: Co-investigator

Title: Health values and treatment of pediatric type 2 diabetes

Description: A study to assess and compare the preferences of adolescents with type 2 diabetes or prediabetes and their parents for states of health impacted by type 2 diabetes.

Role: Consultant

Title: Improving primary care to prevent childhood obesity

Description: A cluster-randomized controlled trial in 10 pediatric practices of a large multi-site group practice in eastern Massachusetts to evaluate the effectiveness and cost-effectiveness of an innovative, sustainable primary care practice change intervention to prevent obesity among young children.

Role: Co-investigator

Title: Economic barriers to obesity prevention and management in children

Description: This project will result in a better understanding of the economic tradeoffs parents make with respect to child food choices, activities, and other aspects of parenting that could affect child overweight.

Title: Cost-effectiveness of live attenuated influenza vaccine for children

Description: This project will evaluate the cost-effectiveness of live attenuated influenza vaccine incorporating the costs and quality of life effects associated with adverse events, wheezing and increased hospitalization, for younger children.

Honors and Awards:

1984-1988	Cornell Tradition Fellowship, Miller Scholarship in Mathematics, Newton North High School Music Department Scholarship, Sons of Italy Scholarship, National Merit Scholarship Semifinalist
1991	Master's Thesis Travel Grant, MIT Program on the Pharmaceutical Industry
1992	William J. Stewart, Jr. Award for extracurricular leadership at MIT
1992	Technology & Policy Award in recognition of founding Women in Technology & Policy
1995-1997	National Library of Medicine Fellowship
1997-1999	National Multiple Sclerosis Society Doctoral Dissertation Fellowship
1998	Lee B. Lusted Student Prize, Society for Medical Decision Making
1999	National Cholesterol Outcomes Research Excellence (CORE) Award, first place
1999-2000	Thomas O. Pyle Fellowship, Harvard Pilgrim Health Care and Harvard Medical School
2002	50 th Anniversary Scholars in Medicine Award, Harvard Medical School
2005	Best General Podium Presentation, International Society for Pharmacoeconomics and Outcomes Research Annual Meeting

Memberships in Professional Societies:

1996-present	AcademyHealth, Member
1996-present	Society for Medical Decision Making, Member Abstract Reviewer (2000-2007) Abstract Scientific Review Committee Co-Chair (2008 Annual Meeting)
2000-present	International Health Economics Association
2001-present	International Society for Pharmacoeconomics and Outcomes Research, Member Abstract Reviewer (2002-2005) Contributed Workshops Co-Chair (2006 Annual International Meeting)
2006-present	American Society for Health Economists, Member

Editorial Positions, Boards, and Peer-Review Service:

1997-present	Ad hoc reviewer	Journal of Health Economics
1999	Ad hoc reviewer	Evaluation and Program Planning
1999	Ad hoc reviewer	Medical Care
2000	Ad hoc reviewer	Annals of Internal Medicine
2000	Ad hoc reviewer	American Journal of Managed Care
2001	Ad hoc reviewer	Pharmacoeconomics
2001	Ad hoc reviewer	Future Drugs
2001-present	Ad hoc reviewer	Medical Decision Making
2003	Ad hoc reviewer	Clinical Therapeutics
2003-present	Ad hoc reviewer	Value in Health
2004-present	Ad hoc reviewer	Vaccine
2004	Ad hoc reviewer	Expert Review of Pharmacoeconomics and Outcomes Research
2004	Ad hoc reviewer	American Journal of Managed Care
2004	Ad hoc reviewer	Pediatrics
2005	Ad hoc reviewer	Archives of Adolescent Medicine
2005-present	Ad hoc reviewer	The Lancet
2005	Ad hoc reviewer	Epidemiologic Reviews
2005	Ad hoc reviewer	Journal of Pediatrics
2006	Ad hoc reviewer	AHRQ
2006-2007	Ad hoc reviewer	Health Affairs
2006	Ad hoc reviewer	Arch Dermatology
2006	Ad hoc reviewer	Human Vaccines
2007	Ad hoc reviewer	Health Policy
2007-2008	Ad hoc reviewer	New England Journal of Medicine
2008	Ad hoc reviewer	Quality of Life Research
2008-present	Editorial Board	PharmacoEconomics

Teaching**1. Local contributions****a. Courses**

1996-1998	HSPH, Management Science, Teaching Assistant 6 graduate students, 4 hours per week, one-half semester.
1996	HSPH, Decision Analysis in Clinical Research, Teaching Assistant 40 graduate students, 4 hours per week, one-half semester.
1996	HSPH, Decision Analysis for Health and Medical Practices, Teaching Assistant 40 graduate students, 4 hours per week, one-half semester.
1997	HSPH, Decision Theory, Teaching Assistant 8 graduate students, 4 hours per week, one semester.
2003-2005	HSPH, Methods for Decision Analysis in Public Health and Medicine, Guest Lecturer 25 students, 6 hours.
2004-2007	Cost-Effectiveness and Cost-Benefit Analysis for Health Program Evaluation, Lecturer 40 graduate students, 6 hours.
2006	HSPH, Decision Analysis Methods in Public Health and Medicine, Primary Instructor 25 students, 14 hours per week, one-half semester.

b. Seminars

- 2000 Department of Ambulatory Care and Prevention, seminar:
Patient-specific factors in clinical decision-making: the relationship between risk attitude and treatment choice in patients with multiple sclerosis
- 2000 Harvard Center for Risk Analysis, Preference Working Group seminar:
Patient preferences for treatments and health states in multiple sclerosis
- 2001 Department of Family and Preventive Medicine, UCSD, seminar:
Introduction to methods for decision analysis in health
- 2002 Dana Farber/ Harvard Cancer Center Outcomes Research Seminar:
Preferences for outcomes prevented by pneumococcal conjugate vaccine:
challenges in using parents as proxies for valuing children's health states
- 2002 Department of Ambulatory Care and Prevention/Pharmaceutical Policy Research
Seminar:
Cost-effectiveness of cholesterol-lowering interventions: challenges of using CEA in
decision-making
- 2003 Department of Ambulatory Care and Prevention, seminar:
Economic analysis of strategies to reduce influenza morbidity in children
- 2004 Department of Ambulatory Care and Prevention, seminar:
Are managed care decisions consistent with public preferences?
- 2005 Department of Ambulatory Care and Prevention, seminar:
The economics of childhood vaccination
- 2006 Harvard Newborn Medicine Epidemiology and Clinical Medicine Conference
Economic values for newborn screening of metabolic disorders and related outcomes
- 2006 Dept. of Health Policy and Management, Harvard School of Public Health, seminar:
Should we vaccinate more children against influenza? Projected health benefits, risks,
and cost-effectiveness
- 2006 Department of Ambulatory Care and Prevention, seminar:
Expanded newborn screening: The effect of false positive test results on quality of life

c. Continuing Medical Education Courses

- 2003-2005 Cost-effectiveness Analysis for Medical Technologies and Pharmaceuticals, Lecturer
40 students, 6 hours

Committee, Organizational, and Volunteer Service:

2002-2006	Chair, Subcommittee on Faculty Maternity Leave Policy (2002-2005) Joint Committee on the Status of Women, Harvard Medical School
2004	Special Reviewer, Research Grants Review Committee, National Eye Institute
2005	Co-Lead, Advisory Committee on Immunization Practices Influenza Working Group, Economic Subgroup, CDC
2005	Member, New Vaccines for Adolescents: National Stakeholders Meeting, CDC/NVAC
2005-present	Member, Database Advisory Panel, National Multiple Sclerosis Society
2006	Member, Peer Review Advisory Panel, Cost-effectiveness of Treatments in Multiple Sclerosis (COSTRIMS) Study
2006	Special Reviewer, Research Grants Review Committee, Decision, Risk and Management Sciences Program, National Science Foundation
2006	Participant, Review Committee, Project MOVE, Centers for Disease Control and Prevention
2006-	Member, Committee on Higher Degrees in Health Policy, Harvard University
2006	Member, ISPOR Fellowship Standards Task Force
2007	Member, Research Grants Review Committee, State of Pennsylvania Department of Health
2007	DACP Faculty Search Committee
2006-2007	
2007-present	Member, Evidence Review Group, Institute for Clinical and Economic Review
2007-present	Member, Genetic Evidence Review Workgroup, Center for Child and Adolescent Health Policy, MassGeneral Hospital for Children
2007	Special Reviewer, Canada Foundation for Innovation
2008	Reviewer, CDC Special Emphasis Panel

Visiting Professorships, Seminars, and Extramural Invited Presentations

Invited Presentations:

2006	Annual Meeting of the New England Consortium of Metabolic Programs Cost-effectiveness of expanded newborn screening (presentation)
2008	Child Health Evaluation and Research (CHEAR) Unit, Department of Pediatrics, University of Michigan Medical School Projected health benefits, risks, and cost-effectiveness of influenza vaccination (research seminar)

National Contributions

Invited Presentations:

- 2000 Annual Meeting of the Society for Medical Decision Making
Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in multiple sclerosis (podium presentation)
- 2001 Annual Meeting of the Society for Medical Decision Making
Do risk attitudes differ across domains and respondent types? (podium presentation)
- 2003 Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention:
Economic analysis of strategies to reduce influenza morbidity in children (presentation)
- 2003 National Immunization Program, Centers for Disease Control and Prevention:
Economic analysis of strategies to reduce influenza morbidity in children (research seminar)
- 2004 Ninth Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research
An economic analysis of rapid tests and antiviral treatments for influenza in children (podium presentation)
- 2005 Tenth Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Costs of delivering adult influenza vaccination in non-traditional settings (podium presentation)
- 2005 Advisory Committee on Immunization Practices Influenza Working Group
Using economic information to prioritize subgroups during influenza vaccine shortages (presentation)
- 2007 11th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Measuring health preferences for use in cost-utility and benefit analyses of interventions in children: Theoretical and methodological considerations (podium presentation)
- 2007 Center for Health Services Research, Henry Ford Health System
Projected costs, risks, and benefits of influenza vaccination of children (research seminar)
- 2007 Conference on Routine Vaccination Against Influenza for Older Children, Centers for Disease Control and Prevention
Projected health benefits, risks, and cost-effectiveness of influenza vaccination: Children aged 5-17 years (presentation)
- 2007 Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention
Cost-effectiveness of influenza vaccination: updated estimates for children aged 2-4 years (presentation)

- 2008 Annual Conference on Vaccine Research, National Foundation for Infectious Diseases
Cost-effectiveness of universal vaccination, Symposium: Universal Vaccination Against
Influenza (symposium speaker)
- 2008 30th Annual Meeting of the Society for Medical Decision Making
Valuing health across the lifespan (podium presentation)

International Contributions

Invited Presentations:

- 2007 Initiative on Medication Management, Policy Analysis, Research & Training (IMPART),
Dalhousie University, Halifax, Nova Scotia, Canada
Introduction to Markov models (seminar/workshop)

Bibliography

Original Articles

1. **Prosser LA**, Koplan JP, Neumann PJ, Weinstein MC. Barriers to using cost-effectiveness analysis in managed care decision making. *Am J Manag Care*. 2000;6(2):173-179.
2. **Prosser LA**, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. *Ann Intern Me*. 2000;132(10):768-779.
3. **Prosser LA**, Kuntz KM, Bar-Or A, Weinstein MC. The relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosis. *Med Decis Making*. 2002;22:506-513.
4. Lieu TA, Thompson KM, **Prosser LA**, O'Brien MA, Yusuf HR, Shefer AM, Weinstein MC, Rickert DL. Emerging issues in vaccine economics: perspectives from the USA. *Expert Rev Vaccines*. 2002;1(4):433-442.
5. **Prosser LA**, Kuntz KM, Bar-Or A, Weinstein MC. Patient and community preferences for treatments and health states in multiple sclerosis. *Mult Scler*. 2003;9:311-319.
6. Wang SJ, Middleton B, **Prosser LA**, Bardon CG, Spurr CD, Carchidi PJ, Kittler AF, Goldszer RC, Fairchild DG, Sussman AJ, Kuperman GJ, Bates DW. A cost-benefit analysis of electronic medical records in primary care. *Am J Med*. 2003;114(5):397-403.
7. **Prosser LA**, Ray GT, O'Brien M, Kleinman K, Santoli J, Lieu TA. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. *Pediatrics*. 2004;113(2):283-290.
8. **Prosser LA**, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. *Value Health*. 2004;7(5):554-568.
9. **Prosser LA**, Bridges CB, Uyeki TM, Rego VH, Ray GT, Meltzer MI, Schwartz B, Thompson WW, Fukuda K, Lieu TA. Values for preventing influenza-related morbidity and vaccine adverse events in children. *Health Qual Life Outcomes*. 2005;3(18):1-16.
10. Simon SR, Majumdar SR, **Prosser LA**, Salem-Schatz S, Warner C, Kleinman K, Miroshnik I, Soumerai SB. Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: a cluster-randomized controlled trial. *Am J Med*. 2005;118(5):521-528.
11. Gupta RS, Bewtra M, **Prosser LA**, Finkelstein JA. Predictors of hospital charges for children admitted with asthma. *Ambul Pediatr*. 2006;6(1):15-20.
12. Wittenberg E, Halpern E, Divi N, **Prosser LA**, Araki SS, Weeks JC. The effect of age, race and gender on preference scores for hypothetical health states. *Qual Life Res*. 2006;15(4):645-653.

13. Skelding PC, Majumdar SR, Kleinman K, Warner C, Salem-Schatz S, Miroshnik I, **Prosser LA**, Simon SR. Clinical and non-clinical correlates of adherence to prescribing guidelines for hypertension in a large managed care organization. *J Clin Hypertension*. 2006;8(6):414-419.
14. **Prosser LA**, Bridges CB, Uyeki TM, Hinrichsen VL, Meltzer MI, Molinari NA, Schwartz B, Thompson WW, Fukuda K, Lieu TA. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. *Emerg Infect Dis*. 2006;12(10):1548-1558.
15. Eisenberg DM, Post DE, Davis RB, Connelly MT, Legedza AT, Hrbek AL, **Prosser LA**, Buring JE, Cherkin DC. Addition of choice of complementary therapies to usual care for acute low back pain: a randomized controlled trial. *Spine*. 2007;32(2):151-8.
16. Simon SR, Rodriguez HP, Majumdar SR, Kleinman K, Warner C, Salem-Schatz S, Miroshnik I, Soumerai SB, **Prosser LA**. Economic analysis of a randomized trial of academic detailing interventions to improve use of antihypertensive medications. *J Clin Hyper*. 2007;9(1):15-20.
17. **Prosser LA**, Wittenberg E. Do risk attitudes differ across domains and respondent types? *Med Decis Making*. 2007;27(3):281-287.
18. **Prosser LA**, O'Brien MA, Molinari NA, Hohman KH, Nichol KL, Wortley PM, Messonnier ML, Lieu TA. Non-traditional settings for influenza vaccination of adults: Costs and cost-effectiveness. *Pharmacoeconomics*. 2008;26(2):163-178.
19. Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, **Prosser LA**. Community and patient values for preventing zoster. *Pharmacoeconomics*. 2008;26(3):235-49.
20. **Prosser LA**, Ladapo JA, Rusinak D, Waisbren SE. Parental tolerance for false-positive newborn screening results. *Arch Pediatr Adolesc Med*. 2008;162(9):870-6.
21. O'Brien MA, **Prosser LA**, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M, Hinrichsen V, Mehta J, Colborne JK, Lieu TA. New Vaccines Against Otitis Media: Projected Benefits and Cost-Effectiveness. *Pediatrics*. 2009;123(6):1452-1463.
22. Lipstein EA, Perrin JM, Waisbren SE, **Prosser LA**. Impact of false-positive newborn metabolic screening results on early health care utilization. *Genet Med*. In press.
23. Lieu TA, Ray GT, Ortega-Sanchez IR, Kleinman K, Rusinak D, **Prosser LA**. Willingness-to-pay for a quality-adjusted life-year based on community member and patient preferences for temporary health states associated with zoster. *PharmacoEconomics*. In press.
24. **Prosser LA**, Kong CY, Rusinak D, Waisbren SE. Projected costs, risks, and benefits of expanded newborn screening for MCADD. *Pediatrics*. In press.

Review Articles

1. **Prosser LA**, Corso PS. Measuring health-related quality of life for child maltreatment: A systematic literature review. *Health Qual Life Outcomes*. 2007;5(1)1-17. Available at: <http://www.hqlo.com/content/5/1/42>.
2. **Prosser LA**, Hammitt JK, Keren R. Measuring health preferences for use in cost-utility and benefit analyses of interventions in children: Theoretical and methodological considerations. *Pharmacoeconomics*. 2007;25(9):713-726.
3. Ladapo JA, Neumann PJ, Keren R, **Prosser LA**. Valuing children's health: a comparison of cost-utility analyses for adult and pediatric health interventions. *Pharmacoeconomics*. 2007;25(10):817-828.
4. Ortega-Sanchez IR, Lee GM, Jacobs RJ, **Prosser LA**, Molinari NA, Zhang X, Baine WB, McCauley MM, Miller T. Projected cost-effectiveness of new vaccines for adolescents in the United States. *Pediatrics*. 2008;121 Suppl 1:S63-78.
5. Wright DR, Wittenberg E, Swan JS, Miksad RA, **Prosser LA**. Methods for measuring temporary health states for cost-utility analyses. *Pharmacoeconomics*. In press.

Chapters

1. **Prosser LA**, Payne K. Discrete Choice. Encyclopedia of Medical Decision Making. Thousand Oaks, CA: SAGE Publications. *In press*.

Editorials/Letters

1. **Prosser LA**, Stinnett AA, Goldman L, Weinstein MC. Cost-effectiveness analyses. *Ann Intern Med* 2001;135(5):383.
2. **Prosser LA**, Lieu TA. Comments on the Prosser et al approach to value disease reduction in children: In reply. *Pediatrics*. 2004;114:1375-1376.
3. **Prosser LA**. Current challenges and future research in measuring preferences for pediatric health outcomes. *J Pediatr*. 2009;155(1):7-9.

Theses

1. **Prosser LA**. Pharmaceutical research and development: the effects of increased competition on human resource strategies [master's thesis]. Boston (MA): MIT; 1992.
2. **Prosser LA**. Patient preferences and economic considerations in treatment decisions for multiple sclerosis [dissertation]. Cambridge (MA): Harvard University; 2000.

Abstracts

(This section only includes presented abstracts not yet published in peer-reviewed journal format)

1. **Prosser LA**, Uyeki TM, Bridges CB, Rego VH, Meltzer M, Schwartz B, Thompson WW, Fukuda K, Lieu TA. An economic analysis of rapid tests and antiviral treatments for influenza in children. *Value in Health*. 2004;3:222-223.
2. **Prosser LA**, Concannon TW, Pearson SD, Hammitt JK. An internet survey of public preferences for characteristics of health interventions. *Med Decis Making*. 2005;25(1):E57.
3. **Prosser LA**, Griffin M, Keren R, Meltzer MI, Ortega-Sanchez I, Herrera G, Messonnier ML, Bridges CB. Using economic evidence to prioritize subgroups during an influenza vaccine shortage. *Med Decis Making*. 2006;26(1):E77.
4. **Prosser LA**, Wittenberg E. Valuing children's health: response issues with using parents as proxies. *Med Decis Making* 2007;25(1):E57.
5. **Prosser LA**, Kong J, Rusinak D, Waisbren SE. Waisbren. Expanded newborn screening: the effect of preferences for false positive test results and dietary treatments on cost-effectiveness. *Med Decis Making*. 2008;25(1):E60.
6. Sandberg EA, **Prosser LA**, Neumann P, Weinstein MC. Health state utilities in children ages 7-10 with attention deficit hyperactivity disorder. *Med Decis Making*. 2008;25(1):E72.
7. Lavelle TA, Uyeki TM, **Prosser LA**. The impact of pediatric adverse events on the cost-effectiveness of oseltamivir. Presented at the 13th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, May 4, 2008, Toronto, ON, Canada.
8. Wright DR, Wittenberg E, Swan JS, Miksad R, **Prosser LA**. A review and critique of methods for measuring temporary health states in cost-utility analyses. Presented at the 13th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, May 5, 2008, Toronto, ON, Canada.
9. Sonnevile K, Lapelle N, Taveras E, Gillman M, **Prosser L**. Economic and other barriers to adopting better nutrition and physical activity behaviors among overweight children. Presented at the 30th Annual Meeting of the Society for Medical Decision Making, October 21, 2008, Philadelphia, PA.
10. Sandberg EA, Thompson K, **Prosser LA**, Neumann P, Weinstein MC. The cost-effectiveness of treatments for attention deficit hyperactivity disorder (ADHD) in children ages 7-10. Presented at the 30th Annual Meeting of the Society for Medical Decision Making, October 21, 2008, Philadelphia, PA.
11. Wang YC, Cheung AM, Bibbins-Domingo K, **Prosser LA**, Cook NR, Trent SA, Goldman L, Gillman M. Effectiveness of blood pressure screening among adolescents on reducing future burden of coronary heart disease. Presented at the 30th Annual Meeting of the Society for Medical Decision Making, October 21, 2008, Philadelphia, PA.
12. **Prosser LA**, Hinrichsen V, Lieu TA. The effect of possible wheezing adverse events on the cost-effectiveness of nasal influenza vaccine in children. Presented at the 30th Annual Meeting of the Society for Medical Decision Making, October 21, 2008, Philadelphia, PA.

13. **Prosser LA**, Rusinak D, Payne K, Uyeki T, Kamimoto L, Messonnier M. Valuing health across the lifespan. Presented at the 30th Annual Meeting of the Society for Medical Decision Making, October 21, 2008, Philadelphia, PA.